|
1
|
Waxman S and Anderson KC: History of the
development of arsenic derivatives in cancer therapy. Oncologist.
6:(suppl 2). S3–S10. 2001. View Article : Google Scholar
|
|
2
|
Chen SJ, Zhou GB, Zhang XW, Mao JH, de Thé
H and Chen Z: From an old remedy to a magic bullet: Molecular
mechanisms underlying the therapeutic effects of arsenic in
fighting leukemia. Blood. 117:6425–6437. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang X, Jia S, Yang S and Yang Y, Yang T
and Yang Y: Arsenic trioxide induces G2/M arrest in hepatocellular
carcinoma cells by increasing the tumor suppressor PTEN expression.
J Cell Biochem. 113:3528–3535. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang X, Jiang F, Mu J, Ye X, Si L, Ning S,
Li Z and Li Y: Arsenic trioxide attenuates the invasion potential
of human liver cancer cells through the demethylation-activated
microRNA-491. Toxicol Lett. 227:75–83. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao JK, Wang LX, Long B, Ye XT, Su JN, Yin
XY, Zhou XX and Wang ZW: Arsenic Trioxide Inhibits Cell Growth and
Invasion via Down-Regulation of Skp2 in Pancreatic Cancer Cells.
Asian Pac J Cancer Prev. 16:3805–3810. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ji H, Li Y, Jiang F, Wang X, Zhang J, Shen
J and Yang X: Inhibition of transforming growth factor beta/SMAD
signal by MiR-155 is involved in arsenic trioxide-induced
anti-angiogenesis in prostate cancer. Cancer Sci. 105:1541–1549.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang H, Gao P and Zheng J: Arsenic
trioxide inhibits cell proliferation and human papillomavirus
oncogene expression in cervical cancer cells. Biochem Biophys Res
Commun. 451:556–561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li H, Zhu X, Zhang Y, Xiang J and Chen H:
Arsenic trioxide exerts synergistic effects with cisplatin on
non-small cell lung cancer cells via apoptosis induction. J Exp
Clin Cancer Res. 28:1102009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Walker AM, Stevens JJ, Ndebele K and
Tchounwou PB: Arsenic trioxide modulates DNA synthesis and
apoptosis in lung carcinoma cells. Int J Environ Res Public Health.
7:1996–2007. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lam SK, Li YY, Zheng CY, Leung LL and Ho
JC: E2F1 downregulation by arsenic trioxide in lung adenocarcinoma.
Int J Oncol. 45:2033–2043. 2014.PubMed/NCBI
|
|
12
|
Zheng CY, Lam SK, Li YY, Fong BM, Mak JC
and Ho JC: Combination of arsenic trioxide and chemotherapy in
small cell lung cancer. Lung Cancer. 82:222–230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang F, Wang X, Liu Q, Shen J, Li Z, Li Y
and Zhang J: Inhibition of TGF-β/SMAD3/NF-κB signaling by
microRNA-491 is involved in arsenic trioxide-induced
anti-angiogenesis in hepatocellular carcinoma cells. Toxicol Lett.
231:55–61. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao YF, Wu DD, Liu SX, Chen X and Ren LF:
Effect of arsenic trioxide on vascular endothelial cell
proliferation and expression of vascular endothelial growth factor
receptors Flt-1 and KDR in gastric cancer in nude mice. World J
Gastroenterol. 13:6498–6505. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aggarwal C, Somaiah N and Simon G:
Antiangiogenic agents in the management of non-small cell lung
cancer: Where do we stand now and where are we headed? Cancer Biol
Ther. 13:247–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weis SM and Cheresh DA: Tumor
angiogenesis: Molecular pathways and therapeutic targets. Nat Med.
17:1359–1370. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bergers G, Brekken R, McMahon G, Vu TH,
Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z and
Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic
switch during carcinogenesis. Nat Cell Biol. 2:737–744. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Deryugina EI and Quigley JP: Pleiotropic
roles of matrix metalloproteinases in tumor angiogenesis:
Contrasting, overlapping and compensatory functions. Biochim
Biophys Acta. 1803:103–120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Humphries JD, Byron A and Humphries MJ:
Integrin ligands at a glance. J Cell Sci. 119:3901–3903. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sakurai T and Kudo M: Signaling pathways
governing tumor angiogenesis. Oncology. 81:(suppl 1). S24–S29.
2011. View Article : Google Scholar
|
|
23
|
Andrae J, Gallini R and Betsholtz C: Role
of platelet-derived growth factors in physiology and medicine.
Genes Dev. 22:1276–1312. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lohela M, Bry M, Tammela T and Alitalo K:
VEGFs and receptors involved in angiogenesis versus
lymphangiogenesis. Curr Opin Cell Biol. 21:154–165. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao Y, Cao R and Hedlund EM: R Regulation
of tumor angiogenesis and metastasis by FGF and PDGF signaling
pathways. J Mol Med (Berl). 86:785–789. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Korc M and Friesel RE: The role of
fibroblast growth factors in tumor growth. Curr Cancer Drug
Targets. 9:639–651. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kuhnert F, Kirshner JR and Thurston G:
Dll4-Notch signaling as a therapeutic target in tumor angiogenesis.
Vasc Cell. 3:202011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Noguera-Troise I, Daly C, Papadopoulos NJ,
Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD and Thurston
G: Blockade of Dll4 inhibits tumour growth by promoting
non-productive angiogenesis. Nature. 444:1032–1037. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ridgway J, Zhang G, Wu Y, Stawicki S,
Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I,
et al: Inhibition of Dll4 signaling inhibits tumour growth by
deregulating angiogenesis. Nature. 444:1083–1087. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Williams CK, Li JL, Murga M, Harris AL and
Tosato G: Up-regulation of the Notch ligand Delta like 4 inhibits
VEGF-induced endothelial cell function. Blood. 107:931–939. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cooney MM, van Heeckeren W, Bhakta S,
Ortiz J and Remick SC: Drug insight: Vascular disrupting agents and
angiogenesis novel approaches for drug delivery. Nat Clin Pract
Oncol. 3:682–692. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang MH, Zang YS, Huang H, Chen K, Li B,
Sun GY and Zhao XW: Arsenic trioxide exerts anti-lung cancer
activity by inhibiting angiogenesis. Curr Cancer Drug Targets.
14:557–566. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie SL, Yang MH, Chen K, Huang H, Zhao XW,
Zang YS and Li B: Efficacy of arsenic trioxide in the treatment of
malignant pleural effusion caused by pleural metastasis of lung
cancer. Cell Biochem Biophys. 71:1325–1333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cattaneo MG, Pola S, Dehò V, Sanguini AM
and Vicentini LM: Alprostadil suppresses angiogenesis in vitro and
in vivo in the murine Matrigel plug assay. Br J Pharmacol.
138:377–385. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Takahashi S: Vascular endothelial growth
factor (VEGF), VEGF receptors and their inhibitors for
antiangiogenic tumor therapy. Biol Pharm Bull. 34:1785–1788. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM,
Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, et al: Use of arsenic
trioxide (As2O3) in the treatment of acute promyelocytic leukemia
(APL): II. Clinical efficacy and pharmacokinetics in relapsed
patients. Blood. 89:3354–3360. 1997.PubMed/NCBI
|
|
38
|
Ma Y, Wang J, Liu L, Zhu H, Chen X, Pan S,
Sun X and Jiang H: Genistein potentiates the effect of arsenic
trioxide against human hepatocellular carcinoma: Role of Akt and
nuclear factor-κB. Cancer Lett. 301:75–84. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Guo W, Tang XD, Tang S and Yang Y:
Preliminary report of combination chemotherapy including Arsenic
trioxide for stage III osteosarcoma and Ewing sarcoma. Zhonghua Wai
Ke Za Zhi. 44:805–808. 2006.(In Chinese). PubMed/NCBI
|
|
40
|
Roboz GJ, Dias S, Lam G, Lane WJ, Soignet
SL, Warrell RP Jr and Rafii S: Arsenic trioxide induces dose- and
time-dependent apoptosis of endothelium and may exert an
antileukemic effect via inhibition of angiogenesis. Blood.
96:1525–1530. 2000.PubMed/NCBI
|
|
41
|
Straub AC, Stolz DB, Ross MA,
Hernández-Zavala A, Soucy NV, Klei LR and Barchowsky A: Arsenic
stimulates sinusoidal endothelial cell capillarization and vessel
remodeling in mouse liver. Hepatology. 45:205–212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lew YS, Brown SL, Griffin RJ, Song CW and
Kim JH: Arsenic trioxide causes selective necrosis in solid murine
tumors by vascular shutdown. Cancer Res. 59:6033–6037.
1999.PubMed/NCBI
|
|
43
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lindner V, Majack RA and Reidy MA: Basic
fibroblast growth factor stimulates endothelial regrowth and
proliferation in denuded arteries. J Clin Invest. 85:2004–2008.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang D, Huang HJ, Kazlauskas A and Cavenee
WK: Induction of vascular endothelial growth factor expression in
endothelial cells by platelet-derived growth factor through the
activation of phosphatidylinositol 3-kinase. Cancer Res.
59:1464–1472. 1999.PubMed/NCBI
|
|
46
|
Kume T: Novel insights into the
differential functions of Notch ligands in vascular formation. J
Angiogenes Res. 1:82009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Scehnet JS, Jiang W, Kumar SR, Krasnoperov
V, Trindade A, Benedito R, Djokovic D, Borges C, Ley EJ, Duarte A
and Gill PS: Inhibition of Dll4-mediated signaling induces
proliferation of immature vessels and results in poor tissue
perfusion. Blood. 109:4753–4760. 2007. View Article : Google Scholar : PubMed/NCBI
|
